Feb. 26, 2015
February 26, 2015. Amarin Corporation and Eddingpharm have entered into an exclusive agreement for Eddingpharm to develop and commercialize Vascepa® (icosapent ethyl) in China, the Hong Kong and Macao Special Administrative Regions and Taiwan.
Under the agreement, Eddingpharm will be responsible for development and commercialization activities. Amarin will provide development assistance supply the finished product. Terms of the agreement include up-front and milestone payments to Amarin of up to $169.0 million, including a non-refundable $15.0 million up-front payment and development, regulatory and sales-based milestone payments of up to an additional $154million. Eddingpharm will also pay Amarin royalties on net sales of Vascepa. Amarin will supply the product to Eddingpharm under negotiated supply terms.